Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | CHIEF TECHNICAL OPS OFFICER | July 09, 2026 | July 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,299 |
Ending reported balance
After 2026-07-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-09 · Exercise / conversion · Acquired 2,464 · Balance 62,763 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. Row 2 · 2026-07-09 · Sale · Disposed 2,464 · Balance 60,299 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.54 · Expires 2035-01-02 | Direct | 45,036 |
Reported balance
After 2026-07-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-09 · Exercise / conversion · Disposed 2,464 · Balance 45,036 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025. F3: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 2,899 |
Reported balance
Holding disclosure · report date 2026-07-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,899 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 4,715 | $18.01 | $84,917.15 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · nonDerivative · entry 5 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,650 | $80.14 | $132,231.00 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · nonDerivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.14 to $80.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,650 | $33.02 | $54,483.00 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,900 | $80.14 | $152,266.00 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,900 | $18.01 | $34,219.00 |
DisclosureSEC source: 0001578850-25-000006 · form4-11262025_051103.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 51,558 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001578850-25-000003 · form4-10072025_051001.xml · derivative · entry 11 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,558 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024 F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,442 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001578850-25-000003 · form4-10072025_051001.xml · derivative · entry 10 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,558 Underlying: Common Stock · 3,442 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024 F8 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,276 | $67.15 | $287,133.40 |
DisclosureSEC source: 0001578850-25-000003 · form4-10072025_051001.xml · nonDerivative · entry 8 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024 F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.00 to $67.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 23,863 | $66.45 | $1,585,696.35 |
DisclosureSEC source: 0001578850-25-000003 · form4-10072025_051001.xml · nonDerivative · entry 7 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,901 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024 F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.00 to $66.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 23,419 | $65.45 | $1,532,773.55 |
DisclosureSEC source: 0001578850-25-000003 · form4-10072025_051001.xml · nonDerivative · entry 6 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,764 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024 F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.00 to $65.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 51,558 | $30.86 | $1,591,079.88 |
DisclosureSEC source: 0001578850-25-000003 · form4-10072025_051001.xml · nonDerivative · entry 5 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024 Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 73 | $67.16 | $4,902.68 |
DisclosureSEC source: 0001578850-25-000003 · form4-10072025_051001.xml · nonDerivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,625 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024 Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,760 | $66.56 | $117,145.60 |
DisclosureSEC source: 0001578850-25-000003 · form4-10072025_051001.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,698 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024 F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.15 to $67.03 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,609 | $65.46 | $105,325.14 |
DisclosureSEC source: 0001578850-25-000003 · form4-10072025_051001.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,458 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024 F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.00 to $65.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,442 | $30.86 | $106,220.12 |
DisclosureSEC source: 0001578850-25-000003 · form4-10072025_051001.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2024 F2 · balance_after: Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 34 | $50.12 | $1,704.22 |
DisclosureSEC source: 0001415889-25-005133 · form4-02212025_050201.xml · nonDerivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 5,907 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 217 RSUs from a February 15, 2024 grant of 870 RSUs. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,578 | $50.12 | $79,095.67 |
DisclosureSEC source: 0001415889-25-005133 · form4-02212025_050201.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,353 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs from a February 15, 2024 grant of 19,000 RSUs and the vesting of 3,000 RSUs from a February 15, 2024 grant of 6,000 RSUs. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 34 | $50.10 | $1,703.26 |
DisclosureSEC source: 0001415889-25-005133 · form4-02212025_050201.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 5,941 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 217 RSUs from a February 15, 2024 grant of 870 RSUs. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,300 | $50.10 | $65,124.80 |
DisclosureSEC source: 0001415889-25-005133 · form4-02212025_050201.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,931 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,750 RSUs from a February 15, 2024 grant of 19,000 RSUs and the vesting of 3,000 RSUs from a February 15, 2024 grant of 6,000 RSUs. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 107 | $44.50 | $4,761.50 |
DisclosureSEC source: 0001415889-25-001290 · form4-01102025_050101.xml · nonDerivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 5,975 F4 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 150 RSUs from a January 6, 2021 grant of 600 RSUs and the vesting of 195 RSUs from a January 7, 2022 grant of 780 RSUs. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,552 | $44.50 | $69,064.00 |
DisclosureSEC source: 0001415889-25-001290 · form4-01102025_050101.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,231 F3 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs and the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 55 | $45.34 | $2,493.70 |
DisclosureSEC source: 0001415889-25-001290 · form4-01102025_050101.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 6,082 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 177 RSUs from a January 5, 2023 grant of 710 RSUs. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,265 | $45.34 | $57,355.10 |
DisclosureSEC source: 0001415889-25-001290 · form4-01102025_050101.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,783 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 47,500 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001019 · form4-01072025_050109.xml · derivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 715 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001019 · form4-01072025_050109.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 6,137 F1 · shares: Restricted stock units granted on January 3, 2025 that vest in four equal installments over four years, commencing on January 3, 2026. F2 · balance_after: Includes 445 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2024, and 401 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2024. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001019 · form4-01072025_050109.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,048 F1 · shares: Restricted stock units granted on January 3, 2025 that vest in four equal installments over four years, commencing on January 3, 2026. F2 · balance_after: Includes 445 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2024, and 401 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2024. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,060 | $0.00 Strike: $51.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · derivative · entry 12 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 2,060 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on February 21, 2023. F9 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 66,956 | $0.00 Strike: $51.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · derivative · entry 11 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,956 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 21, 2023. F9 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,594 | $0.00 Strike: $51.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · derivative · entry 10 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,956 Underlying: Common Stock · 2,594 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 21, 2023. F9 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 277 | $52.76 | $14,614.52 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · nonDerivative · entry 9 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 4,576 F6 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on February 21, 2023. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.65 to $52.91 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,783 | $51.85 | $92,448.55 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · nonDerivative · entry 8 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 4,853 F6 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on February 21, 2023. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.50 to $52.45 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,060 | $51.00 | $105,060.00 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · nonDerivative · entry 7 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 6,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on February 21, 2023. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,611 | $52.72 | $453,971.92 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · nonDerivative · entry 6 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,202 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 21, 2023. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.505 to $52.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 58,345 | $51.97 | $3,032,189.65 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · nonDerivative · entry 5 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,813 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 21, 2023. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.50 to $52.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 66,956 | $51.00 | $3,414,756.00 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · nonDerivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 21, 2023. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 266 | $52.73 | $14,026.18 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,202 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 21, 2023. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.58 to $52.84 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,328 | $51.85 | $120,706.80 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,468 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 21, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.50 to $52.47 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,594 | $51.00 | $132,294.00 |
DisclosureSEC source: 0001415889-24-028289 · form4-12042024_051208.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 21, 2023. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 47,500 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004164 · form4-02162024_050209.xml · derivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2034-02-14 F4 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 870 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004164 · form4-02162024_050209.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 4,576 F3 · shares: Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004164 · form4-02162024_050209.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,202 F2 · shares: Restricted stock units granted on February 15, 2024 that vest in two equal installments over two years, commencing on February 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004164 · form4-02162024_050209.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,202 F1 · shares: Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 21:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 28 | $27.25 | $763.02 |
DisclosureSEC source: 0001415889-24-002174 · form4-02012024_090242.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 3,706 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 93 RSUs from a January 29, 2020 grant of 370 RSUs. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 21:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 618 | $27.25 | $16,840.99 |
DisclosureSEC source: 0001415889-24-002174 · form4-02012024_090242.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,202 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 29, 2020 grant of 10,200 RSUs. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 100 | $29.01 | $2,901.48 |
DisclosureSEC source: 0001415889-24-000908 · form4-01102024_090133.xml · nonDerivative · entry 4 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 3,734 F6 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 150 RSUs from a January 6, 2021 grant of 600 RSUs and the vesting of 195 RSUs from a January 7, 2022 grant of 780 RSUs. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,521 | $29.01 | $44,131.51 |
DisclosureSEC source: 0001415889-24-000908 · form4-01102024_090133.xml · nonDerivative · entry 3 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,820 F5 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs and the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 53 | $28.64 | $1,517.94 |
DisclosureSEC source: 0001415889-24-000908 · form4-01102024_090133.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 3,834 F3 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 177 RSUs from a January 5, 2023 grant of 710 RSUs. F4 · balance_after: Includes 327 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2023 and 301 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2023. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,236 | $28.64 | $35,399.41 |
DisclosureSEC source: 0001415889-24-000908 · form4-01102024_090133.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,341 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs. F2 · balance_after: Includes 327 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2023 and 301 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2023. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 28 | $45.63 | $1,277.58 |
DisclosureSEC source: 0001415889-23-001793 · form4-02022023_090225.xml · nonDerivative · entry 2 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,259 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 92 RSUs from a January 29, 2020 grant of 370 RSUs. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:17 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 630 | $45.63 | $28,745.64 |
DisclosureSEC source: 0001415889-23-001793 · form4-02022023_090225.xml · nonDerivative · entry 1 Almstead Neil Gregory · CIK 0001578850 · CHIEF TECHNICAL OPS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,949 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 29, 2020 grant of 10,200 RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.